Combination drug treatment before surgery for early-stage lung cancer with KRAS G12C mutation
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new combination of drugs before surgery for people with a certain type of lung cancer (KRAS G12C). The goal is to see if these drugs can shrink the tumor and improve chances of successful surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with lung cancer (non-small cell) that can be removed with surgery, at stage IB, II, or IIIA/B.
- Your tumor has a specific gene change called KRAS G12C (confirmed by a blood or tissue test).
- You have not had prior chemotherapy, radiation, or other cancer treatments for this lung cancer.
- You are in generally good health, with no serious heart, lung, or other medical conditions that would interfere.
- You are willing to use effective birth control if you or your partner can become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs (fulzerasib and ivonescimab) for people with a specific gene change (KRAS G12C) in their advanced lung cancer. It aims to see if this combination is safe and effective as the first treatment for this type of cancer.
This trial tests a new pill called Garsorasib for people with advanced non-small cell lung cancer that has a specific gene change called KRAS G12C. It aims to see if the drug can shrink tumors or slow cancer growth in people who haven't had treatment yet.
This study tests a combination of two drugs: one that targets a specific genetic change in your cancer (KRAS G12C) and one that boosts your immune system to fight the cancer. It's for people who haven't had treatment for advanced or metastatic lung cancer yet.
This trial tests a combination of two targeted drugs (JAB-21822 and JAB-3312) compared to standard chemotherapy for people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. It is for people who have not yet received any cancer treatment for their advanced disease.
This trial tests if adding the targeted drug adagrasib to standard immunotherapy and chemotherapy helps people with a specific KRAS G12C mutation in non-squamous non-small cell lung cancer that has spread. It is for people who have not had previous treatment for advanced disease.
This trial tests a new combination of two drugs (SKB264 and glecirasib) for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. It aims to see if this combination can shrink tumors or slow their growth.
Hear when a new Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.